000 01622aam a22004578i 4500
999 _c12860
_d12860
001 9925841653602122
005 20210304155507.0
008 920714t19931993nyua b 001 0 eng
010 _a 92023366
020 _a082478801X
035 _a(OCoLC)26300563
035 _a(WU)2584165-uwmadisondb
035 _a(EXLNZ-01UWI_NETWORK)999699270502121
040 _aDLC
_beng
_cDLC
_dEG-NcFUE
_erda
043 _an-us---
049 _aGZZW
050 0 0 _aRS189
_b.N475 1993
082 0 4 _222
_a363.19460973
_bN
096 _aQV 771 N5318 1992
245 0 0 _aNew drug approval process /
_cedited by Richard A. Guarino.
250 _aSecond edition, revised and expanded.
264 1 _aNew York :
_bM. Dekker,
_c[1993]
264 4 _c©1993
300 _axxi, 469 pages ;
_c24 cm.
336 _atext
_btxt
_2rdacontent
337 _aunmediated
_bn
_2rdamedia
338 _avolume
_bnc
_2rdacarrier
490 0 _aDrugs and the pharmaceutical sciences ;
_vv. 56
504 _aIncludes bibliographical references and index.
610 1 0 _aUnited States.
_bFood and Drug Administration.
650 0 _aDrugs
_xTesting
_xStandards.
650 0 _aDrugs
_xTesting
_xGovernment policy
_zUnited States.
650 0 _aNew products
_xGovernment policy
_zUnited States.
650 2 _aClinical Trials as Topic
_xstandards
_zUnited States.
650 2 _aDrug Evaluation
_xstandards
_zUnited States.
700 1 _aGuarino, Richard A.,
_d1935-
830 0 _aDrugs and the pharmaceutical sciences;
_vv. 56.
942 _2ddc
_cBK